RosA inhibited pro-inflammatory cytokines and microRNAs associated with inflammation, suggesting that RosA may inhibit Warburg effects through the inflammatory pathway, like IL-6/STAT3. MiR-155 was a key mediator of the relationship between inflammation and tumorigenesis. MiR-155 was a target gene that regulated the Warburg effect through inactivating the IL-6/STAT3 pathway. RosA inhibited the Warburg effect in vivo. RosA was a possible therapeutic drug that inhibited the Warburg effect of gastric cancer. Here, IL6 is linked to gastric cancer.